ethyl 4-chloro-6,7-dihydrothieno[3,2-b]pyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: ethyl 4-chloro-6,7-dihydrothieno[3,2-b]pyridine-3-carboxylate
• 英文别名: ethyl 4-chloro-6,7-dihydro-5H-thieno[3,2-b]pyridine-3-carboxylate
• 化学式: C₁₀H₁₂ClNO₂S
• 分子量: 245.73
• InChiKey: GQBWENLJRVMOHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-chloro-6,7-dihydrothieno[3,2-b]pyridine-3-carboxylate 、 4-氯苯肼 、 正丁醇 以 甲醇 为溶剂， 生成 2-(p-chlorophenyl)-2,3,6,7-tetrahydrothieno[3,2-b]pyrazolo[3,4-d]pyridin-3(5H)-one hydrate
  参考文献：
  名称：

  Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine

  摘要：

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。

  公开号：

  US04602014A1
• 作为产物：
  描述：

  ethyl 4-hydroxy-6,7-dihydrothieno[3,2-b]pyridine-3-carboxylate 、 甲烷 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 三氯氧磷 为溶剂， 生成 ethyl 4-chloro-6,7-dihydrothieno[3,2-b]pyridine-3-carboxylate
  参考文献：
  名称：

  Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine

  摘要：

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。

  公开号：

  US04602014A1

文献信息

• Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine
  申请人：Ciba-Geigy Corporation

  公开号：US04602014A1

  公开（公告）日：1986-07-22

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating
  申请人：Ciba-Geigy Corporation

  公开号：US04647566A1

  公开（公告）日：1987-03-03

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  化合物的结构式为IA或IB，其中A代表可选择地取代的饱和双价基团，与其连接的两个碳原子一起代表从可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吩吡喃、四氢噻环戊、二氢呋喃、二氢吡喃、四氢氧杂环戊、二氢吡咯、四氢吡啶和四氢氮杂环庚中选择的融合5、6或7-成员碳环或杂环环; R1代表低碳烷基、苯基，或由低碳烷基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表选择自例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基的芳香杂环基; R2、R3、R3'为氢或低碳烷基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓类受体调节剂。还公开了作为苯二氮卓类受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04814450A1

  公开（公告）日：1989-03-21

  Compounds of the formula formula IA or IB ##STR1## wherein A represent an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.4 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物##STR1##其中A代表一个可以选择性取代的饱和二价基团，与其相连的两个碳原子共同代表一种选择自可选择性取代的融合的5-,6-或7-成员碳环或杂环，所述环选自可选择性取代的融合的环戊烯基，环己烯基，环庚烯基，二氢噻吩基，二氢噻吩并吡喃基，四氢噻环并吡喃基，二氢呋喃基，二氢吡喃基，四氢氧环并吡喃基，二氢吡咯基，四氢吡啶基和四氢氮杂环并吡喃基；R.sub.1代表较低的烷基，苯基，或被较低的烷基，较低的烷氧基，卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表选自例如可选择性取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基的芳香族杂环基；R.sub.2，R.sub.3，R.sub.4'为氢或较低的烷基；以及药学上可接受的盐；用作苯二氮平受体调节剂，用于治疗神经系统疾病。还公开了制药组合物，制备方法和某些中间体，这些中间体用作苯二氮平受体调节剂。
• Certain ring-fused pyrazolo [3,4-d]-pyridin-3-one derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0168350A2

  公开（公告）日：1986-01-15

  Compounds of the formula IA or IB wherein A represents an optically substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7- membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R, represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R2, R3, R3' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式 IA 或 IB 的化合物 其中 A 代表被光学取代的饱和二价基团，该基团与所连接的两个碳原子一起代表一个融合的 5、6 或 7 位碳环或杂环，该环可选自任选取代的融合环戊烯基、环己烯基、环庚烯基、二氢噻吩基、二氢噻喃基、四氢噻吩基、二氢噻吩基二氢噻吩酮、二氢硫吡喃酮、四氢硫杂环酮、二氢呋喃酮、二氢吡喃酮、四氢氧杂环酮、二氢吡咯酮、四氢吡啶酮和四氢氮杂环酮；R，代表低级烷基、苯基或由低级烷基、低级烷氧基、卤素或三氟甲基单取代或二取代的苯基；或 R1 代表芳香杂环基，选自如 下化合物g.任选取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基；R2、R3、R3'为氢或低级烷基；以及药学上可接受的盐；可用作苯并二氮杂卓受体调节剂，用于治疗神经系统疾病。此外，还公开了用作苯二氮卓受体调节剂的药物组合物、制备方法和某些中间体。
• US4602014A
  申请人：——

  公开号：US4602014A

  公开（公告）日：1986-07-22